Latest Psoriasis Stories
- Findings Show Positive Association Between Adherence and Anti-TNF Therapy Compared to Conventional Therapy PARIS, June 11, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced
- Glaucoma Phase II ongoing study will enroll patients to the next higher dose without an interim analysis, no safety issues have been recorded PETACH TIKVA, Israel, June 9, 2014 /PRNewswire/
ResearchMoz.us includes new market research report "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.
LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas,
ResearchMoz.us includes new market research report "Frontier Pharma - Psoriasis - Identifying and Commercializing First-in-Class Innovation: Industry Size, Shares, Growth, Analysis, Trends
LONDON, May 20, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease.
Consensus Statement Supports Adoption of Psoriasis Resolution by the World Health Organization (WHO) at Upcoming 67th World Health Assembly PORTLAND, Ore., May 13, 2014 /PRNewswire-USNewswire/
NEW YORK, May 13, 2014 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc.
Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif.
- totally perplexed and mixed up.